Last updated: June 16, 2026
Extraneal (icodextrin 7.5 g/L) is supplied as a sterile, single-use intraperitoneal peritoneal dialysis solution. Commercial availability depends on (1) the brand’s primary manufacturer and (2) the ability to produce sterile infusion containers to pharmacy and dialysis-device handling specifications.
Who supplies Extraneal (icodextrin) to pharmacies and dialysis providers?
Answer: The product is marketed under the Extraneal brand and supplied by the brand manufacturer and its qualified contract manufacturing network for sterile solution fill-finish. In practice, procurement is executed through wholesalers and dialysis supply chains, but upstream supply comes from the sterile manufacturing site(s) that produce icodextrin peritoneal dialysis solution and package into dialysis-compatible containers.
What supply chain steps control availability for a sterile peritoneal dialysis solution?
Extraneal supply is constrained by:
- Sterile solution manufacture of icodextrin at the required concentration (7.5 g/L).
- Sterile fill-finish capability and validation for large-volume peritoneal dialysis bags.
- Primary packaging compatible with peritoneal dialysis handling and storage conditions.
- Distribution packaging and cold-chain is generally not a major driver for icodextrin, but validated storage ranges are still a manufacturing constraint.
- Regulatory release testing (identity, assay, endotoxin, sterility, container-closure integrity).
What are the upstream manufacturing roles in Extraneal supply?
Answer: The supply network typically breaks into three functions: API or concentrated ingredient procurement, finished-dose sterile manufacturing, and packaging/distribution configuration.
Ingredient sourcing: icodextrin availability and grade control?
For icodextrin-based dialysis solutions, manufacturing needs consistent polymer composition and quality. Suppliers are typically:
- Icodextrin ingredient manufacturers that provide polymeric carbohydrate material meeting pharmacopeial or drug master file specifications.
- Licensed manufacturers that control incoming material testing and traceability for batch release.
Fill-finish and sterile manufacturing suppliers?
The sterile manufacturing supplier(s) for Extraneal are the sites that:
- Dissolve, filter, and aseptically process the icodextrin solution.
- Perform in-process controls and sterility assurance steps.
- Fill into dialysis bags and complete container-closure integrity validation.
Primary packaging and bag/closure suppliers?
Peritoneal dialysis product supply also depends on packaging component suppliers:
- Bag film and closure systems meeting permeability and integrity requirements for long dwell use.
- Sterile barrier systems and validated packaging processes.
Which companies distribute Extraneal in the US channel?
Answer: Extraneal is distributed through national wholesalers and dialysis-related distributors once marketed. Channel distributors handle logistics, returns, and replenishment, while the product’s upstream manufacturing responsibility remains with the marketing authorization holder and its manufacturing sites.
What to check in procurement: NDC-level supplier mapping
For buying purposes, the cleanest way to identify the supplying entity at the order-entry level is:
- The NDC tied to the specific vial/bag size and presentation.
- The manufacturer name shown on invoices or the package labeling for the NDC.
This avoids confusion from relabeling and different distribution subsidiaries.
How do supplier constraints affect Extraneal availability?
Answer: The key drivers are sterile manufacturing capacity, validated bag/closure supply, and batch release capacity for sterility/endotoxin and physicochemical specifications.
Common bottlenecks for sterile peritoneal dialysis products
- Aseptic processing line downtime.
- Filter integrity testing failures and batch holds.
- Container-closure integrity testing capacity.
- Packaging component shortages (closures, seals, bag film lots).
- Regulatory release backlogs during surge demand.
Are there multiple manufacturing sites for Extraneal?
Answer: Multi-site supply is common for sterile injectable or sterile solution products, but the specific number and identities of sites depends on the labeling and FDA manufacturing listings for each presentation.
What matters for “which suppliers” in a compliance-heavy context?
For procurement, the “supplier” most relevant for audits is the finished-dose manufacturing site listed for:
- cGMP manufacturing of the final dosage form.
- Sterile fill-finish steps.
- Responsible party for batch release.
Key decision list: how to identify the exact supplier(s) for your region and presentation
Use this order of operations for procurement or sourcing diligence:
- Pull the NDC for your bag size/presentation and confirm the labeled manufacturer on package/labeling.
- Map the manufacturer name to the FDA listing for the NDC presentation (establishes cGMP site responsibility).
- Verify whether the product uses one or multiple finished-dose sites (audits and continuity planning).
- Cross-check the availability pattern by presentation strength and pack size, since production constraints can hit one SKU harder than others.
Key Takeaways
- Extraneal supply is driven by sterile manufacturing and validated dialysis-compatible bag/closure packaging, not by generic API sourcing alone.
- The operational “supplier” for the market is the finished-dose manufacturing site(s) behind the NDC presentation, with distribution handled by wholesalers and dialysis channels.
- Supplier identification should be NDC- and presentation-specific, using the labeled manufacturer and the FDA manufacturing listing for that exact product configuration.
FAQs
1) Who makes Extraneal icodextrin 7.5 g/L peritoneal dialysis solution?
The manufacturer shown on the product labeling for your exact NDC/presentation is the finished-dose supplier; distribution is handled by wholesalers and dialysis distributors.
2) Can Extraneal be sourced from multiple suppliers or just one site?
Many sterile injectables and sterile solutions operate with more than one qualified manufacturing site. Whether that applies to your specific Extraneal NDC presentation depends on the listing for that product configuration.
3) What is the main supply constraint for Extraneal availability?
Sterile fill-finish capacity and validated packaging component availability, followed by regulatory release testing throughput.
4) Do icodextrin ingredient suppliers affect Extraneal batch release?
Yes. Ingredient quality and polymer composition control are part of release testing and batch disposition for icodextrin-containing products.
5) How do I identify the correct supplier for contracting or GMP audits?
Match the NDC presentation to the labeled manufacturer and the FDA manufacturing listing for that exact dosage form and container-closure system.
References (APA)
- U.S. Food and Drug Administration. (n.d.). Drug registrations and listings (NDC manufacturer listings). FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
